An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-003883-20

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the safety and tolerability of imatinib as measured by rate and severity of adverse events.


Critère d'inclusion

  • gastrointestinal stromal tumors - adjuvant treatment after surgical tumor resection